GOSS
Gossamer Bio, Inc.
+0.90 (+8.23%)11.86USD171K成交股數5.8B市值–本益比(近四季)108.8股價營收比-19.6%營收年增(近四季)2026-11-04下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 0 |
| 近 180 天 淨額 | 0 |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | 01-05 | Aranda Richard | Chief Medical Officer | A 獲配股票 | 93.8K | – | – | 463K | SEC |
| 2026-01-02 | 01-05 | Peterson Caryn | EVP, Regulatory Affairs | A 獲配股票 | 84.5K | – | – | 259K | SEC |
| 2026-01-02 | 01-05 | Smith Robert Paul JR | Chief Commercial Officer | A 獲配股票 | 93.8K | – | – | 261K | SEC |
| 2026-01-02 | 01-05 | Hasnain Faheem | President & CEO | A 獲配股票 | 280K | – | – | 838K | SEC |
| 2026-01-02 | 01-05 | Giraudo Bryan | COO/CFO | A 獲配股票 | 116K | – | – | 390K | SEC |
| 2026-01-02 | 01-05 | Christian Waage | EVP, Tech Ops and Admin | A 獲配股票 | 84.5K | – | – | 814K | SEC |
| 2025-10-01 | 10-02 | Hasnain Faheem | President & CEO | A 獲配股票 | 438K | – | – | 558K | SEC |
| 2025-10-01 | 10-02 | Smith Robert Paul JR | Chief Commercial Officer | A 獲配股票 | 163K | – | – | 163K | SEC |
| 2025-10-01 | 10-02 | Aranda Richard | Chief Medical Officer | A 獲配股票 | 163K | – | – | 369K | SEC |
| 2025-10-01 | 10-02 | Peterson Caryn | EVP, Regulatory Affairs | A 獲配股票 | 125K | – | – | 175K | SEC |
| 2025-10-01 | 10-02 | Christian Waage | EVP, Tech Ops and Admin | A 獲配股票 | 125K | – | – | 711K | SEC |
| 2025-10-01 | 10-02 | Giraudo Bryan | COO/CFO | A 獲配股票 | 181K | – | – | 274K | SEC |
| 2025-08-19 | 08-20 | Milligan Sandra | Director | P 公開市場買進 | 26.1K | 1.92 | 50K | 58.0K | SEC |
| 2024-06-24 | 06-25 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 1.9K | 0.66 | 1K | 197K | SEC |
| 2024-06-21 | 06-24 | Hasnain Faheem | President & CEO | P 公開市場買進 | 372K | 0.67 | 249K | 5.4M | SEC |
| 2024-06-18 | 06-20 | Giraudo Bryan | COO/CFO | P 公開市場買進 | 100K | 0.59 | 59K | 480K | SEC |
| 2024-06-17 | 06-20 | Smith Robert Paul JR | Chief Commercial Officer | P 公開市場買進 | 25.0K | 0.60 | 15K | 25.0K | SEC |
| 2024-03-27 | 03-28 | Hasnain Faheem | President & CEO | S 公開市場賣出 | 23.2K | 1.16 | 27K | 120K | SEC |
| 2024-03-27 | 03-28 | Christian Waage | EVP, Tech Ops and Admin | S 公開市場賣出 | 6.4K | 1.16 | 7K | 586K | SEC |
| 2024-03-27 | 03-28 | Giraudo Bryan | COO/CFO | S 公開市場賣出 | 6.4K | 1.16 | 7K | 92.7K | SEC |
| 2024-03-18 | 03-19 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 4.0K | 1.33 | 5K | 199K | SEC |
| 2024-03-18 | 03-19 | Peterson Caryn | EVP, Regulatory Affairs | S 公開市場賣出 | 4.0K | 1.33 | 5K | 49.8K | SEC |
| 2023-11-15 | 11-17 | Milligan Sandra | Director | P 公開市場買進 | 32.0K | 0.79 | 25K | 32.0K | SEC |
| 2023-11-13 | 11-14 | Giraudo Bryan | COO/CFO | P 公開市場買進 | 200K | 0.56 | 112K | 380K | SEC |
| 2023-07-24 | 07-26 | Christian Waage | EVP, Tech Ops and Admin | A 獲配股票 | 13.5K | 1.82 | 25K | 45.9K | SEC |
| 2023-07-24 | 07-26 | Hasnain Faheem | President & CEO | A 獲配股票 | 540K | 1.82 | 983K | 5.0M | SEC |
| 2023-07-24 | 07-26 | Giraudo Bryan | COO/CFO | A 獲配股票 | 54.0K | 1.82 | 98K | 180K | SEC |
| 2023-06-22 | 06-26 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 1.8K | 1.29 | 2K | 198K | SEC |
| 2023-04-04 | 04-05 | Giraudo Bryan | COO/CFO | P 公開市場買進 | 55.0K | 1.02 | 56K | 126K | SEC |
| 2023-03-22 | 03-22 | Hasnain Faheem | President & CEO | P 公開市場買進 | 441K | 1.14 | 502K | 4.5M | SEC |
| 2023-03-21 | 03-22 | Hasnain Faheem | President & CEO | P 公開市場買進 | 269K | 1.20 | 323K | 4.1M | SEC |
| 2023-03-20 | 03-22 | Hasnain Faheem | President & CEO | P 公開市場買進 | 169K | 1.03 | 174K | 3.8M | SEC |
| 2023-03-20 | 03-22 | Giraudo Bryan | COO/CFO | P 公開市場買進 | 50.0K | 0.97 | 49K | 71.0K | SEC |
| 2023-03-20 | 03-22 | Christian Waage | EVP, Tech Ops and Admin | P 公開市場買進 | 18.5K | 1.20 | 22K | 32.4K | SEC |
| 2023-03-16 | 03-20 | Carter Laura | Chief Scientific Officer | S 公開市場賣出 | 6.0K | 1.10 | 7K | 76.3K | SEC |
| 2023-03-16 | 03-20 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 7.6K | 1.10 | 8K | 199K | SEC |
| 2023-03-16 | 03-20 | Peterson Caryn | EVP, Regulatory Affairs | S 公開市場賣出 | 7.6K | 1.10 | 8K | 53.9K | SEC |
| 2022-10-24 | 10-27 | Carter Laura | Chief Scientific Officer | S 公開市場賣出 | 4.9K | 12.07 | 59K | 82.3K | SEC |
| 2022-10-24 | 10-25 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 4.8K | 12.07 | 57K | 205K | SEC |
| 2022-10-24 | 10-25 | Peterson Caryn | EVP, Regulatory Affairs | S 公開市場賣出 | 4.8K | 12.07 | 57K | 61.4K | SEC |
| 2022-10-24 | 10-25 | Carter Laura | Chief Scientific Officer | S 公開市場賣出 | 4.9K | 12.07 | 59K | 82.3K | SEC |
| 2022-07-15 | 07-15 | Christian Waage | EVP, Tech Ops and Admin | P 公開市場買進 | 6.9K | 7.21 | 50K | 13.9K | SEC |
| 2022-07-15 | 07-15 | Giraudo Bryan | COO/CFO | P 公開市場買進 | 13.9K | 7.21 | 100K | 21.0K | SEC |
| 2022-07-15 | 07-15 | Hasnain Faheem | President & CEO | P 公開市場買進 | 139K | 7.21 | 1,000K | 3.6M | SEC |
| 2022-07-15 | 07-15 | Carter Laura | Chief Scientific Officer | P 公開市場買進 | 6.9K | 7.21 | 50K | 87.2K | SEC |
| 2022-07-01 | 07-05 | Carter Laura | Chief Scientific Officer | S 公開市場賣出 | 8.8K | 8.25 | 73K | 80.2K | SEC |
| 2022-06-22 | 06-23 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 1.8K | 6.88 | 12K | 210K | SEC |
| 2022-05-04 | 05-05 | Carter Laura | Chief Scientific Officer | S 公開市場賣出 | 1.3K | 7.20 | 9K | 89.0K | SEC |
| 2022-03-23 | 03-24 | Giraudo Bryan | COO/CFO | S 公開市場賣出 | 10.7K | 8.92 | 96K | 99.2K | SEC |
| 2022-03-23 | 03-24 | Christian Waage | EVP, Tech Ops and Admin | S 公開市場賣出 | 10.7K | 8.92 | 96K | 579K | SEC |
| 2022-03-23 | 03-24 | Hasnain Faheem | President & CEO | S 公開市場賣出 | 19.0K | 8.92 | 170K | 143K | SEC |
| 2022-03-16 | 03-17 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 6.3K | 8.28 | 52K | 212K | SEC |
| 2022-03-16 | 03-17 | Carter Laura | Chief Scientific Officer | S 公開市場賣出 | 5.0K | 8.28 | 41K | 90.3K | SEC |
| 2022-03-16 | 03-17 | Peterson Caryn | EVP, Regulatory Affairs | S 公開市場賣出 | 6.3K | 8.28 | 52K | 66.2K | SEC |
| 2021-10-25 | 10-26 | Aranda Richard | Chief Medical Officer | S 公開市場賣出 | 2.4K | 12.25 | 29K | 217K | SEC |
| 2021-10-25 | 10-26 | Peterson Caryn | EVP, Regulatory Affairs | S 公開市場賣出 | 2.4K | 12.25 | 29K | 72.5K | SEC |
| 2021-10-25 | 10-26 | Carter Laura | Chief Scientific Officer | S 公開市場賣出 | 2.4K | 12.25 | 29K | 95.3K | SEC |
| 2021-06-30 | 07-01 | Carter Laura | Chief Scientific Officer | A 獲配股票 | 25.0K | – | – | 97.7K | SEC |
| 2021-06-21 | 06-22 | Aranda Richard | Chief Medical Officer | A 獲配股票 | 15.0K | – | – | 220K | SEC |
| 2021-05-03 | 05-05 | Carter Laura | Chief Scientific Officer | A 獲配股票 | 10.8K | – | – | 72.7K | SEC |
| 2021-04-16 | 04-20 | Peterson Caryn | EVP, Regulatory Affairs | A 獲配股票 | 10.8K | – | – | 74.8K | SEC |
| 2021-03-23 | 03-25 | Giraudo Bryan | Chief Financial Officer | S 公開市場賣出 | 5.5K | 9.48 | 52K | 110K | SEC |
| 2021-03-23 | 03-25 | Christian Waage | EVP & General Counsel | S 公開市場賣出 | 5.5K | 9.48 | 52K | 588K | SEC |
| 2021-03-23 | 03-25 | Salter-Cid Luisa | Chief Scientific Officer | S 公開市場賣出 | 5.5K | 9.48 | 52K | 206K | SEC |
| 2021-02-25 | 03-01 | Salter-Cid Luisa | Chief Scientific Officer | A 獲配股票 | 45.0K | – | – | 212K | SEC |
| 2021-02-25 | 03-01 | Giraudo Bryan | Chief Financial Officer | A 獲配股票 | 45.0K | – | – | 115K | SEC |
| 2021-02-25 | 03-01 | Christian Waage | EVP & General Counsel | A 獲配股票 | 45.0K | – | – | 594K | SEC |
| 2021-02-25 | 03-01 | Hasnain Faheem | President & CEO | A 獲配股票 | 163K | – | – | 163K | SEC |
| 2020-10-14 | 10-14 | Hasnain Faheem | Director | P 公開市場買進 | 96.5K | 10.36 | 1,000K | 3.5M | SEC |
| 2020-10-14 | 10-14 | Giraudo Bryan | Chief Financial Officer | P 公開市場買進 | 3.0K | 10.01 | 30K | 7.1K | SEC |
| 2020-10-14 | 10-14 | Christian Waage | EVP & General Counsel | P 公開市場買進 | 2.5K | 9.53 | 24K | 7.0K | SEC |
| 2020-06-23 | 06-23 | Giraudo Bryan | Chief Financial Officer | P 公開市場買進 | 2.0K | 12.96 | 26K | 4.1K | SEC |
| 2020-02-14 | 02-19 | Salter-Cid Luisa | Chief Scientific Officer | A 獲配股票 | 46.5K | – | – | 167K | SEC |
| 2020-02-14 | 02-19 | Christian Waage | EVP & General Counsel | A 獲配股票 | 46.5K | – | – | 548K | SEC |
| 2020-02-14 | 02-19 | Giraudo Bryan | Chief Financial Officer | A 獲配股票 | 46.5K | – | – | 70.4K | SEC |
| 2020-02-14 | 02-19 | Gujrathi Sheila | President & CEO | A 獲配股票 | 190K | – | – | 190K | SEC |
| 2020-02-14 | 02-19 | Dupont Jakob | Chief Medical Officer | A 獲配股票 | 46.5K | – | – | 46.5K | SEC |
| 2019-12-31 | 01-02 | Salter-Cid Luisa | Chief Scientific Officer | G 贈與 | 4.0K | – | – | 120K | SEC |
| 2019-12-30 | 12-31 | Dupont Jakob | Chief Medical Officer | M 選擇權執行 | 40.0K | 10.71 | 428K | 40.0K | SEC |
| 2019-12-30 | 12-31 | Dupont Jakob | Chief Medical Officer | S 公開市場賣出 | 40.0K | 15.00 | 600K | 0 | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| 德劭 D. E. Shaw & Co., Inc. | 41.0M | 6.7M | +40.6M (+10418%) | 加碼 |
| 683 Capital Management, LLC | 39.2M | 6.5M | +34.2M (+684%) | 加碼 |
| DeepCurrents Investment Group LLC | 37.7M | 6.0M | 新進 | 新進 |
| Context Capital Management, LLC | 28.9M | 4.8M | 新進 | 新進 |
| Worth Venture Partners, LLC | 25.0M | 4.1M | 新進 | 新進 |
| Kalehua Capital Management LLC | 22.3M | 3.7M | +4.6M (+26%) | 加碼 |
| AQR CAPITAL MANAGEMENT LLC | 15.6M | 2.6M | +5.5M (+54%) | 加碼 |
| WOLVERINE ASSET MANAGEMENT LLC | 12.9M | 2.1M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 11.6M | 1.9M | +10.4M (+855%) | 加碼 |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.4M | 1.6M | +21.4K (+0%) | 加碼 |
| ARCH Venture Management, LLC | 8.1M | 1.3M | 不變 | 持平 |
| BARCLAYS PLC | 7.8M | 1.3M | +4.8M (+155%) | 加碼 |
| Octagon Capital Advisors LP | 7.8M | 1.3M | 不變 | 持平 |
| BlackRock, Inc. | 7.7M | 1.3M | −9.2M (-54%) | 減碼 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 7.6M | 1.2M | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 7.4M | 1.2M | +2.7M (+55%) | 加碼 |
| SAMSARA BIOCAPITAL, LLC | 7.2M | 1.2M | 不變 | 持平 |
| Qube Research & Technologies Ltd | 7.1M | 1.2M | +2.1M (+44%) | 加碼 |
| Corient Private Wealth LP | 5.6M | 927K | +1.6M (+41%) | 加碼 |
| Siren, L.L.C. | 5.2M | 857K | 不變 | 持平 |
| HHLR ADVISORS, LTD. | 5.0M | 819K | 不變 | 持平 |
| UBS Group AG | 3.1M | 510K | +1.2M (+64%) | 加碼 |
| Squarepoint Ops LLC | 2.6M | 421K | −842K (-25%) | 減碼 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5M | 409K | −2.5M (-50%) | 減碼 |
| 千禧 MILLENNIUM MANAGEMENT LLC | 2.4M | 395K | +2.2M (+1182%) | 加碼 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 170 -15 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 28 / 43 / 62 / 44 |
| 機構合計持股 · 佔流通股 | 382M · 78.1% |
| 合計季末市值 | 59.8M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 82.6M |
|---|---|
| 與上期比 | -4.8% |
| 佔流通股數 | 16.90% |
| 日均成交量 | 29.6M |
| 回補天數 | 2.8 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 82.6M | -4.8% | 16.90% | 29.6M | 2.8 |
| 2026-08-14 | 86.8M | -8.6% | 17.75% | 11.8M | 7.4 |
| 2026-07-31 | 95.0M | +29.8% | 19.43% | 63.6M | 1.5 |
| 2026-07-15 | 73.2M | +36.3% | 14.97% | 19.3M | 3.8 |
| 2026-06-30 | 53.7M | -4.5% | 10.98% | 16.7M | 3.2 |
| 2026-06-15 | 56.2M | -10.5% | 11.50% | 16.5M | 3.4 |
| 2026-05-29 | 62.8M | +53.8% | 12.85% | 22.1M | 2.8 |
| 2026-05-15 | 40.8M | +2.0% | 8.35% | 3.6M | 11.5 |
| 2026-04-30 | 40.0M | -0.4% | 8.19% | 5.2M | 7.7 |
| 2026-04-15 | 40.2M | +7.2% | 8.22% | 8.3M | 4.9 |
| 2026-03-31 | 37.5M | +2.4% | 7.67% | 13.6M | 2.8 |
| 2026-03-13 | 36.6M | +5.5% | 7.49% | 13.6M | 2.7 |
| 2026-02-27 | 34.7M | +11.7% | 7.10% | 45.0M | 1.0 |
| 2026-02-13 | 31.1M | +16.1% | 6.36% | 6.1M | 5.1 |
| 2026-01-30 | 26.8M | +6.2% | 5.48% | 4.7M | 5.7 |
| 2026-01-15 | 25.2M | +4.6% | 5.16% | 4.6M | 5.4 |
| 2025-12-31 | 24.1M | +18.7% | 4.93% | 5.2M | 4.7 |
| 2025-12-15 | 20.3M | -13.3% | 4.15% | 3.5M | 5.7 |
| 2025-11-28 | 23.4M | -4.0% | 4.79% | 2.9M | 8.2 |
| 2025-11-14 | 24.4M | -2.0% | 5.00% | 2.6M | 9.5 |
| 2025-10-31 | 24.9M | -6.9% | 5.10% | 3.1M | 8.0 |
| 2025-10-15 | 26.8M | -2.3% | 5.47% | 3.2M | 8.2 |
| 2025-09-30 | 27.4M | +14.2% | 5.60% | 4.3M | 6.4 |
| 2025-09-15 | 24.0M | +8.8% | 4.91% | 5.7M | 4.2 |
| 2025-08-29 | 22.0M | +7.5% | 4.51% | 3.1M | 7.1 |
| 2025-08-15 | 20.5M | +9.4% | 4.19% | 3.0M | 6.8 |